Correction of the article

In the results section of the abstract the two sentencesFor 79 % of the radiopharmaceuticals, the new calculations gave a lower effective dose per unit administered activity than earlier estimated." Should be "For 63 % of the radiopharmaceuticals, the new calculations gave a lower effective dose per unit administered activity than earlier estimated.""As a mean for all radiopharmaceuticals, the effective dose was 25 % lower." Should be"As a mean for all radiopharmaceuticals, the effective dose was 11 % lower."

In the results section in the main article four sentences should be changed"The calculated values are lower than earlier presented values for 79 % of the radiopharmaceuticals." Should be "The calculated values are lower than earlier presented values for 63 % of the radiopharmaceuticals.""As a mean for all 338 radiopharmaceuticals, the values are 25 % lower." Should be "As a mean for all 338 radiopharmaceuticals, the values are 11 % lower.""The effective doses are larger for females than for males in 62 % of all 338 radiopharmaceuticals." Should be "The effective doses are larger for females than for males in 99 % of all 338 radiopharmaceuticals.""Only for ^125^I Iodine Hippuran with unilateral renal blockage and an abnormal kidney function there is a difference of more than 100 % between the new and the old E/A~0~ values." Should be "Only for ^99m^Tc Apcitide and ^99m^Tc labelled colloids, small colloids and normal liver condition there is a difference of more than 100 % between the new and the old E/A~0~ values."

In the Discussion section in the main article eight sentences should be changed"For radiopharmaceuticals with a significant uptake in adipose tissue as for ^14^C- and ^3^H-labelled neutral fat and free fatty acids or in the male gonads, the effective dose will be higher for males than for females." Should be "For radiopharmaceuticals with a significant uptake in adipose tissue as for ^14^C- and ^3^H-labelled neutral fat and free fatty acids, the effective dose will be higher for males than for females.""For ^18^ F-labelled substances, E/A~0~ varies between 0.013 and 0.019 mSv/MBq (less than a factor of 1.5)." Should be "For ^18^ F-labelled substances, E/A~0~ varies between 0.013 and 0.021 mSv/MBq (a factor of 1.6).""For ^11^C-substances, E/A~0~ varies between 0.0025 and 0.0055 mSv/MBq (around a factor of 2.2)." Should be "For ^11^C-substances, E/A~0~ varies between 0.0011 and 0.0087 mSv/MBq (around a factor of 8.0). ""Also for ^99m^Tc-labelled substances, the range of E/A~0~ values is limited to 0.0017 to 0.016 mSv/MBq (a factor of 9.6)." Should be "Also for ^99m^Tc-labelled substances, the range of E/A~0~ values is limited to 0.0022 to 0.020 mSv/MBq (a factor of 8.8).""For all the ^18^ F substances, there is a reduction in effective dose estimation by 29 % in average." Should be "For all the ^18^ F substances, there is a reduction in effective dose estimation by 26 % in average.""For ^11^C-substances, two radiopharmaceuticals show a higher effective dose and 11 have a lower effective dose than previously published values." Should be "For ^11^C-substances, nine radiopharmaceuticals show a higher effective dose and four have a lower effective dose than previously published values.""In 50 of the 62 ^99m^Tc-substances, the effective dose estimations give lower values than previous estimations." Should be "In 38 of the 62 ^99m^Tc-substances, the effective dose estimations give lower values than previous estimations.""Using the new estimations, the collective effective dose is estimated at 292 manSv, i.e. 13 % lower value than earlier estimated." Should be "Using the new estimations, the collective effective dose is estimated at 295 manSv, i.e. 12 % lower value than earlier estimated."

In the Conclusions there are two sentences that should be changed"For 268 radiopharmaceuticals out of 338, the new calculations show lower effective dose values than previous estimates." Should be "For 212 radiopharmaceuticals out of 338, the new calculations show lower effective dose values than previous estimates.""For 68 radiopharmaceuticals, the new calculations results in an increased value of the estimated effective dose." Should be "For 120 radiopharmaceuticals, the new calculations results in an increased value of the estimated effective dose."

Figure [1](#Fig1){ref-type="fig"} should be changed to (only the figure not the text)Fig. 1A histogram of the relative difference between different dose values. The relative difference between the old published effective dose per unit administered activity and the effective dose values calculated with the new phantom (ICRP 110) and with (1) the new (ICRP 103) and (2) the previous (ICRP 60) tissue weighting factors. The arrow indicates identical results between old and new estimations

Almost all numbers have been changed in Table [1](#Tab1){ref-type="table"} and a new corrected Table [1](#Tab1){ref-type="table"} is presented below (table text to Table [1](#Tab1){ref-type="table"} does not need to be changed)Table 1Effective dose from the 55 radiopharmaceuticals in ICRP publication 106, determined using three different methodsRadiopharmaceuticals(E/A~0~)1 \[mSv/MBq\](E/A~0~)2 \[mSv/MBq\]((E/A~0~)2-(E/A~0~)1)/(E/A~0~)1 \[%\](E/A~0~)3 \[mSv/MBq\]((E/A~0~)3-(E/A~0~)1)/(E/A~0~)1 \[%\](E/A~0~)3 male \[mSv/MBq\](E/A~0~)3 female \[mSv/MBq\]PhantomMIRDICRP/ICRUICRP/ICRUICRP/ICRUICRP/ICRUw~T~ICRP 60ICRP 60ICRP 103ICRP 103ICRP 103^3^H Tritium labelled neutral fat & free fatty acids2.2E-019.81E-02−551.80E-01−182.44E-011.16E-01^11^C Carbon acetate3.5E-034.26E-03223.65E-0343.33E-033.97E-03^11^C Carbon amino acids5.6E-035.76E-0335.26E-03−64.91E-035.61E-03^11^C Carbon brain receptor substances4.3E-033.70E-03−143.62E-03−163.23E-034.00E-03^11^C Carbon methionine8.4E-035.88E-03−305.11E-03−394.50E-035.72E-03^11^C Carbon (2-^11^C)thymidine2.7E-033.01E-03113.04E-03132.77E-033.32E-03^11^C Carbon, realistic maximum1.1E-026.04E-03−455.08E-03−544.36E-035.80E-03^14^C Carbon labelled neutral fat & free fatty acids2.1E + 001.88E + 00−102.65E + 00263.14E + 002.15E + 00^14^C Carbon labelled urea, normal case, orally administered3.1E-022.67E-02−142.72E-02−122.46E-022.98E-02^15^O Oxygen water1.1E-039.63E-04−129.33E-04−158.72E-049.93E-04^18^ F Fluoride labelled amino acids2.3E-022.27E-02−12.07E-02−101.92E-022.21E-02^18^ F Fluoride labelled brain receptor substances2.8E-022.01E-02−282.02E-02−281.82E-022.22E-02^18^ F Fluoride FDG1.9E-021.69E-02−111.71E-02−101.53E-021.88E-02^18^ F Fluoride L-dopa2.5E-021.75E-02−301.57E-02−371.37E-021.76E-02^51^Cr Chromium EDTA2.0E-031.65E-03−181.43E-03−291.23E-031.62E-03^67^Ga Gallium citrate1.0E-019.29E-02−79.08E-02−98.14E-021.00E-01^68^Ga Gallium labelled EDTA4.0E-022.41E-02−402.14E-02−471.89E-022.40E-02^75^Se Selenium labelled amino acids2.2E + 002.39E + 0082.27E + 0032.14E + 002.39E + 00^75^Se Selenium labelled bile acid SeHCAT6.9E-013.01E-01−563.48E-01−503.16E-013.79E-01^99m^Tc Technetium apcitide4.7E-031.13E-021401.19E-021531.10E-021.29E-02^99m^Tc Technetium labelled small colloids, intratumoural adm. time to removal 18 h2.0E-033.14E-03573.96E-03983.49E-034.43E-03^99m^Tc Technetium labelled small colloids, intratumoural adm time to removal 6 h1.2E-031.78E-03482.24E-03861.98E-032.50E-03^99m^Tc Technetium EC, normal renal function6.3E-034.63E-03−273.66E-03−423.04E-034.29E-03^99m^Tc Technetium ECD7.7E-035.97E-03−235.64E-03−275.01E-036.27E-03^99m^Tc Technetium furifosmin, exercise8.9E-036.57E-03−266.78E-03−246.16E-037.40E-03^99m^Tc Technetium furifosmin, resting subject1.0E-026.99E-03−307.19E-03−286.53E-037.85E-03^99m^Tc Technetium labelled HIG7.0E-039.83E-03409.42E-03358.93E-039.92E-03^99m^Tc Technetium labelled HM-PAO9.3E-031.05E-02139.78E-0358.95E-031.06E-02Tc-99 m Technetium labelled IDA derivatives, normal hepato-biliary conditions1.7E-029.39E-03−459.73E-03−438.93E-031.05E-02^99m^Tc Technetium labelled MAA1.1E-021.34E-02221.40E-02271.27E-021.53E-02^99m^Tc Technetium labelled MAG3, normal renal function7.0E-035.12E-03−274.00E-03−433.29E-034.70E-03^99m^Tc Technetium labelled non-absorbable markers, orally administered fluids1.9E-021.06E-02−441.07E-02−449.93E-031.14E-02^99m^Tc Technetium labelled non-absorbable markers, orally administered solids2.4E-021.13E-02−531.15E-02−521.07E-021.24E-02^99m^Tc Technetium labelled MIBI, exercise7.9E-036.55E-03−176.29E-03−205.80E-036.78E-03^99m^Tc Technetium labelled MIBI, resting subject9.0E-036.81E-03−246.61E-03−276.14E-037.07E-03^99m^Tc Technetium labelled monoclonal antibodies, intact antibody1.2E-021.17E-02−31.08E-02−109.95E-031.16E-02^99m^Tc Technetium pertechnegas1.2E-021.52E-02261.50E-02251.39E-021.61E-02^99m^Tc Technetium pertechnetate, intravenous blocking agent given4.2E-034.34E-0334.02E-03−43.58E-034.46E-03^99m^Tc Technetium pertechnetate, intravenous no blocking agent given1.3E-021.60E-02231.58E-02221.48E-021.68E-02^99m^Tc Technetium pertechnetate orally, no blocking agent1.4E-026.48E-03−546.36E-03−555.83E-036.89E-03^99m^Tc Technetium labelled phosphates and phosphonates, normal uptake and excretion5.7E-034.55E-03−203.99E-03−303.38E-034.59E-03^99m^Tc Technetium labelled erythrocytes7.0E-031.06E-02511.11E-02591.02E-021.20E-02^99m^Tc Technetium technegas1.5E-021.79E-02191.90E-02271.71E-022.08E-02^99m^Tc Technetium tetrofosmin, exercise6.9E-035.54E-03−205.67E-03−185.15E-036.20E-03^99m^Tc Technetium tetrofosmin, resting subject8.0E-035.92E-03−266.15E-03−235.57E-036.72E-03^99m^Tc Technetium labelled white blood cells (leukocytes)1.1E-021.28E-02161.02E-02−79.24E-031.12E-02^111^In Indium labelled HIG1.7E-012.23E-01312.15E-01261.99E-012.31E-01^111^In Indium labelled monoclonal antibodies, intact antibody3.3E-012.88E-01−132.74E-01−172.49E-012.99E-01^111^In Indium octreotide5.4E-026.74E-02255.93E-02105.34E-026.51E-02^123^I Iodide, thyroid uptake 35 %2.2E-012.59E-01182.13E-01−31.95E-012.30E-01^123^I Iodine BMIPP1.6E-021.70E-0261.71E-0271.56E-021.87E-02^123^I Iodine IPPA1.6E-021.72E-0271.72E-0281.56E-021.87E-02^123^I Iodine labelled brain receptor substances5.0E-023.60E-02−283.65E-02−273.30E-024.00E-02^123^I Iodine Hippuran, normal renal function1.2E-028.88E-03−267.06E-03−415.98E-038.15E-03^123^I Iodine MIBG1.3E-021.67E-02281.67E-02281.51E-021.82E-02^123^I Iodine labelled monoclonal antibodies, intact antibody2.9E-023.29E-02132.94E-0212.68E-023.21E-02^124^I Iodide, thyroid uptake 35 %1.5E + 011.41E + 01−61.15E + 01−231.05E + 011.25E + 01^125^I Iodide, thyroid uptake 35 %1.4E + 011.85E + 01321.50E + 0171.38E + 011.62E + 01^131^I Iodide, thyroid uptake 35 %2.4E + 012.68E + 01112.15E + 01−101.98E + 012.33E + 01^131^I Iodine, Hippuran, normal renal function5.2E-021.89E-02−641.53E-02−711.29E-021.78E-02^131^I Iodine, labelled monoclonal antibodies, intact antibody4.7E-014.40E-01−63.59E-01−243.26E-013.94E-01^131^I Iodine NP591.8E + 002.02E + 00121.74E + 00−31.60E + 001.89E + 00^201^Tl Thallium ion1.4E-011.27E-01−101.02E-01−279.90E-021.05E-01.

A new Supplemental file is given in a separate file named "Additional file [1](#MOESM1){ref-type="media"}: Table S1".

Additional file 1 {#Sec1}
=================

Additional file 1: Table S1.Effective dose from all the radiopharmaceuticals published by the ICRP, determined using three different methods. (E/A~0~) 1 is the previously published effective dose per unit administered activity (E/A~0~) by ICRP, (E/A~0~)2 is (E/A~0~) dose calculated with the new phantoms and old tissue weighting factors while (E/A~0~) 3 is with the new phantoms and new weighting factors. (E/A~0~)2-(E/A~0~) 1))/ (E/A~0~)1 and ((E/A~0~) 3-(E/A~0~)1)/ (E/A~0~)1 is the difference in % of the new values compared to the old. (E/A~0~)3 male and (E/A~0~)3 are the effective dose estimations generated from the equivalent dose of each gender separately using the new phantoms and new weighting factors. (DOCX 65 kb)
